{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:59:58Z","timestamp":1793192398583,"version":"4.5.0"},"reference-count":62,"publisher":"American Society for Clinical Investigation","issue":"22","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["Ovarian Cancer Research Program award W81XWH-18-OCRP-IIRA"],"award-info":[{"award-number":["Ovarian Cancer Research Program award W81XWH-18-OCRP-IIRA"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100022074","name":"Sumitomo Dainippon Pharma Oncology","doi-asserted-by":"crossref","award":["Sumitomo Dainippon Pharma Oncology"],"award-info":[{"award-number":["Sumitomo Dainippon Pharma Oncology"]}],"id":[{"id":"10.13039\/501100022074","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:p>\n                    Despite advances in ovarian cancer (OC) therapy, recurrent OC remains a poor-prognosis disease. Because of the close interaction between OC cells and the tumor microenvironment (TME), it is important to develop strategies that target tumor cells and engage components of the TME. A major obstacle in the development of OC therapies is the identification of targets with expression limited to tumor surface to avoid off-target interactions. The follicle-stimulating hormone receptor (FSHR) has selective expression on ovarian granulosa cells and is expressed on 50%\u201370% of serous OCs. We generated mAbs targeting the external domain of FSHR using in vivo\u2013expressed FSHR vector. By high-throughput flow analysis, we identified multiple clones and downselected D2AP11, a potent FSHR surface\u2013targeted mAb. D2AP11 identifies important OC cell lines derived from tumors with different mutations, including BRCA1\/2, and lines resistant to a wide range of therapies. We used D2AP11 to develop a bispecific T cell engager. In vitro addition of PBMCs and T cells to D2AP11-TCE induced specific and potent killing of different genetic and immune escape OC lines, with EC\n                    <jats:sub>50<\/jats:sub>\n                    s in the ng\/ml range, and attenuated tumor burden in OC-challenged mouse models. These studies demonstrate the potential utility of biologics targeting FSHR for OC and perhaps other FSHR-positive cancers.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.162553","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T14:01:06Z","timestamp":1669039266000},"source":"Crossref","is-referenced-by-count":20,"title":["A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy"],"prefix":"10.1172","volume":"7","author":[{"given":"Devivasha","family":"Bordoloi","sequence":"first","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4904-5050","authenticated-orcid":true,"given":"Alfredo","family":"Perales-Puchalt","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet J.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-6668","authenticated-orcid":true,"given":"Xizhou","family":"Zhu","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Liaw","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-320X","authenticated-orcid":true,"given":"Daniel H.","family":"Park","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-3804","authenticated-orcid":true,"given":"Daniel W.","family":"Kulp","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-2360","authenticated-orcid":true,"given":"Rugang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[{"name":"Vaccine & Immunotherapy Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004173"},{"key":"B2","unstructured":"American Cancer Society. Key Statistics for Ovarian Cancer. hhttps:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html Accessed November 22, 2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00952-5"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577869"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/232817"},{"key":"B6"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0492"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071167"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2659"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198310133091503"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/32.11.2040"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3349"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.391"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2013.811806"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2637"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7534"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.219"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00273-4"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001283"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature03206"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.06.001"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.63721"},{"key":"B26","unstructured":"CellModelPassports. https:\/\/cellmodelpassports.sanger.ac.uk\/ Accessed September 28, 2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1178"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1688038"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00058"},{"key":"B30","unstructured":"FDA. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma Updated January 26, 2022. Accessed April 20, 2022"},{"key":"B31","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ Updated May, 31, 2022. Accessed September 28, 2022"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4721"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00707"},{"issue":"11","key":"B34","first-page":"5127","article-title":"Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon","volume":"44","author":"Akiyama","year":"1984","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102699"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.10.062"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126086"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0047"},{"key":"B39","unstructured":"Broad Institute. DepMap portal. https:\/\/depmap.org\/portal\/ Accessed September 28, 2022"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0670-5"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569061"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0297"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0926-0"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw020"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.225"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.90"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.014"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0001"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.07.003"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00850-6"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx441"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0272"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61338-6"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061607"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.002"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.039"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.01.056"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.214"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.014"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/162553\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:27:00Z","timestamp":1779146820000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/162553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":62,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11,22]]},"published-print":{"date-parts":[[2022,11,22]]}},"alternative-id":["10.1172\/jci.insight.162553"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.162553","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"article-number":"e162553"}}